STAT+: Up and down the ladder: The latest comings and goings

STAT PlusPharmalot Up and down the ladder: The latest comings and goings Manage alerts for this article Save this story for later Share this article By Ed SilvermanNov. 6, 2026 Pharmalot Columnist, Senior Writer Ed Silverman[email protected]Ed’s stories explore prescription drug pricing, affordability and access, as well issues surrounding patents, litigation, and legislation. He is also the author of the morning Pharmalittle newsletter and the afternoon Pharmalot newsletter.

Hired someone new and exciting? Promoted a rising star? Finally solved that hard-to-fill spot?

Share the news with us, and we’ll share it with others. That’s right. Send us your changes, and we’ll find a home for them.

Don’t be shy. Everyone wants to know who is coming and going. And here is our regular feature in which we highlight a different person each week.

This time around, we note that MetaVia hired Sarah Browne as chief medical officer. Previously, she was a clinical development consultant to Soufflé Therapeutics and, prior to that, she was vice president, clinical development at Altimmune.Advertisement But all work and no play can make for a dull chief medical officer. STAT+ Exclusive Story Already have an account?

Log in This article is exclusive to STAT+ subscribers Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts. Already have an account? Log in Monthly $39 Totals $468 per year $39/month Get Started Totals $468 per year Starter $30 for 3 months, then $399/year $30 for 3 months Get Started Then $399/year Annual $399 Save 15% $399/year Get Started Save 15% 11+ Users Custom Savings start at 25%!

Request A Quote Request A Quote Savings start at 25%! 2-10 Users $300 Annually per user $300/year Get Started $300 Annually per user View All Plans To read the rest of this story subscribe to STAT+. Subscribe Log In biotechnology, jobs, Pharmaceuticals, STAT+ Submit a correction requestReprints Ed Silverman Pharmalot Columnist, Senior Writer Ed’s stories explore prescription drug pricing, affordability and access, as well issues surrounding patents, litigation, and legislation.

He is also the author of the morning Pharmalittle newsletter and the afternoon Pharmalot newsletter. Newsletter From the lab to the medicine chest, these are the must-read drug industry updates of the day Recommended Pharmalot November 6, 2026 STAT Plus: Pharmalittle: We’re reading about a Novartis gene therapy, faster U.K. drug reviews, and more Pharmalot November 5, 2026 STAT Plus: Pharma’s trade group spent heavily on search ads to sway public opinion Advertisement Pharmalot November 5, 2026 STAT Plus: Novartis cites cases of previously unknown tumors possibly tied to its SMA gene therapy Pharmalot November 5, 2026 STAT Plus: Pharmalittle: We’re reading about India’s new manufacturing rules, clinical trials in China, and more November 4, 2026 STAT Plus: Pharmalittle: We’re reading about CVS plans to split up, FDA inspections in India and China and more Subscriber Picks